Star Combo Valuation
| S66 Stock | 0.15 0.01 7.14% |
Star Combo seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Star Combo Pharma from inspecting the company fundamentals such as Return On Equity of 0.0224, shares outstanding of 135.08 M, and Operating Margin of 0.04 % as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 0.608 | Enterprise Value 16.9 M | Enterprise Value Ebitda 6.0764 | Price Sales 0.7788 | Trailing PE 15 |
Overvalued
Today
Please note that Star Combo's price fluctuation is out of control at this time. Calculation of the real value of Star Combo Pharma is based on 3 months time horizon. Increasing Star Combo's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Star Combo's intrinsic value may or may not be the same as its current market price of 0.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.15 | Real 0.12 | Hype 0.15 |
The intrinsic value of Star Combo's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Star Combo's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Star Combo Pharma helps investors to forecast how Star stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Star Combo more accurately as focusing exclusively on Star Combo's fundamentals will not take into account other important factors: Star Combo Cash |
|
Star Combo Total Value Analysis
Star Combo Pharma is at this time forecasted to have takeover price of 16.93 M with market capitalization of 20.26 M, debt of 4.03 M, and cash on hands of 6.5 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Star Combo fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.93 M | 20.26 M | 4.03 M | 6.5 M |
Star Combo Investor Information
About 94.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.61. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Star Combo Pharma last dividend was issued on the 14th of October 2024. Based on the analysis of Star Combo's profitability, liquidity, and operating efficiency, Star Combo Pharma is performing exceptionally good at this time. It has a great probability to report excellent financial results in February.Star Combo Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Star Combo has an asset utilization ratio of 60.77 percent. This implies that the Company is making USD0.61 for each dollar of assets. An increasing asset utilization means that Star Combo Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Star Combo Ownership Allocation
Star Combo Pharma shows a total of 135.08 Million outstanding shares. Star Combo Pharma has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 93.57 % of Star Combo outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Star Combo Profitability Analysis
The company reported the revenue of 26.02 M. Net Income was 747.33 K with profit before overhead, payroll, taxes, and interest of 4.82 M.About Star Combo Valuation
The stock valuation mechanism determines Star Combo's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Star Combo Pharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Star Combo. We calculate exposure to Star Combo's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Star Combo's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.3 M | 4.8 M |
Additional Tools for Star Stock Analysis
When running Star Combo's price analysis, check to measure Star Combo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Star Combo is operating at the current time. Most of Star Combo's value examination focuses on studying past and present price action to predict the probability of Star Combo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Star Combo's price. Additionally, you may evaluate how the addition of Star Combo to your portfolios can decrease your overall portfolio volatility.